One of the first compounds used was trastuzumab, a HER2/neu-antibody for the use in HER2+ breast cancer[6] and the tyrosine kinase inhibitor imatinib, which targets the BCR/ABL1-kinase in chronic myeloid leukemia[7]. This evidence concerns the gene ERBB2 and breast carcinoma.